Diamond Business Summary

Diamond (6815.TWO) operates as Taiwan’s first publicly listed evergreen venture capital firm specializing in the biotechnology and life sciences sectors. The company generates revenue primarily through realized capital gains from the strategic exit of portfolio companies via initial public offerings (IPOs) or mergers and acquisitions, supplemented by dividend income from its mature holdings. Its business model is structured around four primary segments: new drug research and development, high-end medical devices, innovative medical service technologies, and agricultural biotechnology. Within the competitive landscape of Asian biotech investment, Diamond competes with regional peers such as CDIB Capital, Vivo Capital, and Qiming Venture Partners. It distinguishes itself by utilizing a permanent capital structure that allows for longer-term investment horizons compared to traditional 10-year private equity funds, serving as a strategic gateway for institutional capital into the diversified biotech market. The leadership team is anchored by Chairman Pan-Chyr Yang, an academician and former President of National Taiwan University with a background in internal medicine and biomedical innovation. He is supported by Vice Chairman Tsu-Der Lee, who brings decades of experience in healthcare management and venture capital, and President Yolanda Wu, who manages the firm’s investment strategy and portfolio operations. Diamond was founded in 2013 through a strategic alliance between the Microbio Group and major Taiwanese financial conglomerates, including Fubon Financial Holding, Taishin Financial Holding, and the Ruentex Group. These founding shareholders continue to serve as significant backers and board members, providing Diamond with a robust capital base and a vast network of institutional resources that facilitate global deal sourcing and the commercialization of high-potential medical startups.